Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Q BioMed Inc QBIO

Healthcare Biotechnology
Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated... see more

Recent & Breaking News (GREY:QBIO)

Q BioMed and Collaborator Chemveda Life Sciences Announce Potential Chemotherapeutic Breakthrough in Liver Cancer

PR Newswire August 20, 2019

Q BioMed Announces Updates on Commercialization of Non-Opioid Metastatic Cancer Pain Drug

Newsfile July 11, 2019

Q BioMed Announces Updates on Commercialization of Non-Opioid Metastatic Cancer Pain Drug

GlobeNewswire July 11, 2019

Q BioMed Files for Orphan Drug Designation with U.S. FDA for Autism Spectrum Disorder Subtype

Newsfile June 28, 2019

Q BioMed Files for Orphan Drug Designation with U.S. FDA for Autism Spectrum Disorder Subtype

GlobeNewswire June 28, 2019

Q BioMed Responds to OTC Markets Request for Clarity on Promotional Activity

Newsfile June 24, 2019

Q BioMed Advances QBM-001 for the Treatment of Autism Spectrum Disorder Subtype

Newsfile June 4, 2019

Q BioMed Advances QBM-001 for the Treatment of Autism Spectrum Disorder Subtype

GlobeNewswire June 4, 2019

Biotechnology Accelerator, Q BioMed Inc., Selects 5W Public Relations as Agency of Record

PR Newswire May 30, 2019

QBioMed Counter Punching Glaucoma with Powerful Combinations

Press Releases May 16, 2019

Q BioMed Research Partner Mannin Research to Attend ARVO 2019 Annual Meeting

Newsfile April 24, 2019

QBioMed Research Partner Mannin Research to Attend ARVO 2019 Annual Meeting

GlobeNewswire April 24, 2019

In a Major Breakthrough, Q BioMed Discovers First Biomarkers for Pediatric Nonverbal Autism Subgroup

Newsfile April 10, 2019

Biotechnology Accelerator Positions Multiple Shots on Goal in the Multi-Billion Dollar Glaucoma Market with Commercialization Target in the Near Term

Newsfile March 27, 2019

Q BioMed and Mannin Research to Develop GDF15 Biomarker Glaucoma Diagnostic Kit Through Collaboration with McMaster University

GlobeNewswire March 19, 2019

Q Biomed's Set to Transform Multi-Billion Dollar Glaucoma Market

PR Newswire March 12, 2019

Q BioMed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression from Washington University

Newsfile March 11, 2019

Q BioMed's Autism Spectrum Disorder Drug Development Program Featured in February Issue of Leading Pharma/Biotech Newspaper

GlobeNewswire February 26, 2019

Interviews with CEO Denis Corin of Q BioMed and CEO George Nikopoulos of Mannin Research

Newsfile February 22, 2019

Q BioMed Responds to OTC Markets Request for Clarity on Investor Awareness Activity

PR Newswire February 7, 2019